Equities researchers at Leerink Swann initiated coverage on shares of Illumina Inc. (NASDAQ:ILMN) in a report issued on Thursday. The firm set a “market perform” rating on the life sciences company’s stock.

ILMN has been the topic of several other reports. Vetr lowered Illumina from a “buy” rating to a “hold” rating and set a $133.50 price target on the stock. in a research report on Wednesday. JPMorgan Chase & Co. lifted their price target on Illumina from $185.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 27th. Cantor Fitzgerald restated a “hold” rating and set a $165.00 price target on shares of Illumina in a research report on Wednesday, July 27th. Mizuho lifted their price target on Illumina from $138.00 to $148.00 and gave the company a “neutral” rating in a research report on Wednesday, July 27th. Finally, Zacks Investment Research upgraded Illumina from a “sell” rating to a “hold” rating and set a $186.00 price target on the stock in a research report on Thursday, July 28th. Four equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and seven have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $153.71.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) traded up 1.45% during midday trading on Thursday, reaching $135.06. The company had a trading volume of 388,747 shares. The company has a 50-day moving average of $155.38 and a 200-day moving average of $152.98. The stock has a market capitalization of $19.81 billion, a PE ratio of 45.32 and a beta of 1.24. Illumina has a 12-month low of $127.10 and a 12-month high of $196.47.

Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, November 1st. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.87 by $0.10. Illumina had a return on equity of 23.76% and a net margin of 18.72%. The firm had revenue of $607 million for the quarter, compared to analysts’ expectations of $628.06 million. During the same period in the previous year, the firm earned $0.80 earnings per share. The business’s revenue was up 10.4% compared to the same quarter last year. On average, analysts predict that Illumina will post $3.33 EPS for the current fiscal year.

In other Illumina news, Director Daniel Bradbury sold 600 shares of the firm’s stock in a transaction on Wednesday, August 17th. The stock was sold at an average price of $168.42, for a total transaction of $101,052.00. Following the transaction, the director now directly owns 17,065 shares in the company, valued at approximately $2,874,087.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert S. Epstein sold 300 shares of the firm’s stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $170.27, for a total value of $51,081.00. Following the transaction, the director now owns 7,224 shares in the company, valued at $1,230,030.48. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ILMN. Capital Research Global Investors increased its position in Illumina by 17.1% in the second quarter. Capital Research Global Investors now owns 13,085,071 shares of the life sciences company’s stock valued at $1,836,882,000 after buying an additional 1,910,346 shares during the last quarter. Capital World Investors increased its position in shares of Illumina by 218.0% in the second quarter. Capital World Investors now owns 1,463,000 shares of the life sciences company’s stock worth $205,376,000 after buying an additional 1,003,000 shares in the last quarter. Baillie Gifford & Co. increased its position in shares of Illumina by 3.8% in the second quarter. Baillie Gifford & Co. now owns 18,615,061 shares of the life sciences company’s stock worth $2,613,182,000 after buying an additional 682,010 shares in the last quarter. Rockefeller Financial Services Inc. increased its position in shares of Illumina by 11,812.5% in the second quarter. Rockefeller Financial Services Inc. now owns 271,962 shares of the life sciences company’s stock worth $38,177,000 after buying an additional 269,679 shares in the last quarter. Finally, American Capital Management Inc. bought a new position in shares of Illumina during the third quarter worth about $43,373,000. Institutional investors own 95.26% of the company’s stock.

Illumina Company Profile

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

5 Day Chart for NASDAQ:ILMN

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.